Smith Group Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Smith Group Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,620	Closed	-$214K	–	446
2016 Q4	$214K	Sell	11,620 -370	-3%	-$7.2K	0.01%	246
2016 Q3	$227K	Buy	11,990 +230	+2%	+$4.17K	0.01%	237
2016 Q2	$190K	Sell	11,760 -102,650	-90%	-$1.45M	0.01%	264
2016 Q1	$1.37M	Buy	114,410 +109,100	+2,055%	+$1.29M	0.04%	149
2015 Q4	$76K	Buy	+5,310	New	+$70.1K	﹤0.01%	306

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Smith Group Asset Management's AMPH Position: Q1 2017 in Review

Smith Group Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2017, closing a stake of 11,620 shares — an estimated $214K sold.

Smith Group Asset Management first reported a position in AMPH in Q4 2015 and held it in 5 quarters. The position peaked at $1.37M in Q1 2016. 116 funds tracked by Wall St. Rank hold AMPH as of Q1 2017.

Smith Group Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Smith Group Asset Management sold 11,620 Amphastar Pharmaceuticals shares in Q1 2017, an estimated $214K.
Smith Group Asset Management first reported a position in Amphastar Pharmaceuticals in Q4 2015 and held it in 5 quarters.
Smith Group Asset Management's Amphastar Pharmaceuticals position peaked at $1.37M in Q1 2016.
116 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2017.

Based on Smith Group Asset Management's 13F filing for Q1 2017, filed 4 May 2017.